Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Istradefylline
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Marvel Biosciences Extends Collaboration with iBraiN Institute on Rett Syndrome
Details : The collaboration aims to advance clinical development of the company's early-stage product MB204 (istradefylline) for the treatment of Rett syndrome.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 26, 2024
Lead Product(s) : Istradefylline
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : iBraiN Institute
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase IV
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Istradefylline Effect Protocol on Parkinson's Disease Tremor
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2023
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Istradefylline for Parkinson Disease With Cognitive Impairment
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 19, 2022
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Kyowa Kirin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Evaluate Abuse Potential of Istradefylline
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 20, 2015
Lead Product(s) : Istradefylline
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Mild Hepatic Impairment on the Pharmacokinetics of Istradefylline
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 03, 2014
Lead Product(s) : Istradefylline
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effect of Rifampin on the Metabolism of Istradefylline in Healthy Volunteers.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 25, 2014
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 23, 2013
Lead Product(s) : Istradefylline
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Kyowa Hakko Bio
Deal Size : Inapplicable
Deal Type : Inapplicable